Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Latanoprost
Drug ID BADD_D01251
Description Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.[A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. Another benefit latanoprost is that it can be administered once a day.[A184490]
Indications and Usage Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension.[L8357] Latanoprost may be combined in a product with [Netarsudil], a rho kinase inhibitor, for the same indications.[L8369] In addition to the above indications, the Canadian monograph for this drug also approves latanoprost for the treatment of elevated intraocular pressure as a result of angle-closure glaucoma that has been treated with peripheral iridotomy or laser iridoplasty.[L8366]
Marketing Status approved; investigational
ATC Code S01EE01
DrugBank ID DB00654
KEGG ID D00356
MeSH ID D000077338
PubChem ID 5311221
TTD Drug ID D0C6NM
NDC Product Code 65727-026; 82187-1002; 71205-154; 62991-3186; 65427-007; 82231-111; 50090-1920; 59762-0333; 54893-0010; 63190-0710; 65326-004; 61314-547; 65862-872; 0009-5172; 12079-0475; 42385-039; 51552-1385; 51927-4864; 68245-0002; 81997-001; 10695-048; 90027-006; 47335-317; 70069-421; 65035-128; 71684-0547; 73212-027; 55545-0462; 71052-041; 24208-463; 64980-516; 68071-4612; 40016-001; 61556-050; 0013-8303; 24002-0018; 73377-237
UNII 6Z5B6HVF6O
Synonyms Latanoprost | PhXA34 | PHXA41 | Xalatan
Chemical Information
Molecular Formula C26H40O5
CAS Registry Number 130209-82-4
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal sensation in eye06.01.01.0010.000144%Not Available
Abortion missed18.01.01.0020.000067%Not Available
Acne23.02.01.0010.000121%Not Available
Ageusia17.02.07.001; 07.14.03.0030.000175%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000045%
Anosmia22.04.03.006; 17.04.04.0010.000342%
Application site erythema08.02.01.001; 23.03.06.005; 12.07.01.001--Not Available
Application site irritation12.07.01.003; 08.02.01.003--Not Available
Application site pain12.07.01.004; 08.02.01.0040.000045%Not Available
Arrhythmia02.03.02.0010.000247%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.0010.000810%
Arthropathy15.01.01.0030.000310%Not Available
Asthenopia06.01.01.0020.000045%Not Available
Asthma22.03.01.002; 10.01.03.0100.000301%Not Available
Atrial tachycardia02.03.03.0040.000112%
Atrioventricular block second degree02.03.01.0050.000090%
Back disorder15.03.05.0030.000099%Not Available
Back pain15.03.04.005--
Blepharal pigmentation23.05.01.009; 06.06.04.0140.000045%Not Available
Blepharitis23.03.04.012; 06.04.04.0010.000175%Not Available
Blindness06.02.10.003; 17.17.01.0030.000427%Not Available
Blindness unilateral06.02.10.007; 17.17.01.0160.000202%Not Available
Blister12.01.06.002; 23.03.01.0010.000328%Not Available
Blood pressure fluctuation24.06.01.0020.000045%Not Available
Bradycardia02.03.02.0020.000247%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm10.01.03.012; 22.03.01.0040.000090%
Burning sensation17.02.06.001; 08.01.09.0290.000679%Not Available
Cataract06.06.01.0010.001462%
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene